Global Coronavirus Partnering 2014-2021
発行: Current Partnering, a division of Wildwood Ventures Limited
ページ情報: 英文 650+ Pages
当レポートでは、コロナウィルスに関する昨今 (2014年から2021年) の提携取引の動向について分析し、全体的な取引形成件数の推移や、財務面 (支払条件) での傾向、主要企業による取引形成の動き、契約条件の傾向、技術別・治療標的別の傾向などを調査すると共に、近年の主要な提携取引の詳細情報を取りまとめてお届けいたします。
The Global Coronavirus Partnering 2014-2021 report provides comprehensive understanding and unprecedented access to the coronavirus partnering agreements entered into by the worlds leading healthcare companies.
Global Coronavirus Partnering 2014 to 2021 provides the full collection of Coronavirus disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Trends in Coronavirus partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Coronavirus partnering agreement structure
Coronavirus partnering contract documents
Top Coronavirus deals by value
Most active Coronavirus dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Coronavirus disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Coronavirus deals.
The report presents financial deal terms values for Coronavirus deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Coronavirus dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Coronavirus dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Coronavirus deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Coronavirus dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Coronavirus deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Coronavirus partnering deals by specific Coronavirus target announced since 2014. The chapter is organized by specific Coronavirus therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Coronavirus partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Coronavirus partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Coronavirus technologies and products.
Global Coronavirus Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Coronavirus trends and structure of deals entered into by leading companies worldwide.
Global Coronavirus Partnering 2014 to 2021 includes:
In Global Coronavirus Partnering 2014 to 2021, available deals and contracts are listed by:
The Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals. Analyzing actual contract agreements allows assessment of the following:
Global Coronavirus Partnering 2014 to 2021 provides the reader with the following key benefits: